Download full-text PDF

Source
http://dx.doi.org/10.1164/arrd.1969.100.6.866DOI Listing

Publication Analysis

Top Keywords

pulmonary plasmacytoma
4
plasmacytoma case
4
case report
4
pulmonary
1
case
1
report
1

Similar Publications

Pleural thickening can be the result of inflammation or infection but can also have a neoplastic origin. Depending on the clinical context, a pleural lesion or mass is often initially suspected of malignancy. Benign pleural tumors are rare, and their appearance on ultrasound (US) is also described less frequently than pleural metastases or malignancies.

View Article and Find Full Text PDF

Introduction And Importance: Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm, constituting around 3 % of plasma cell malignancies. SEP typically presents as a single tumor, either in bone or soft tissue, without systemic disease, and is often misdiagnosed due to its nonspecific symptoms. Diagnosis requires biopsy and extensive imaging studies to exclude multiple myeloma and other malignancies.

View Article and Find Full Text PDF

Primary pulmonary plasmacytoma: A case report.

Medicine (Baltimore)

December 2024

Department of Respiratory and Critical Care Medicine, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.

Article Synopsis
  • Extramedullary plasmacytoma is a rare malignant tumor found in tissues outside of bone marrow, with primary pulmonary plasmacytoma (PPP) being particularly uncommon and diagnosed through biopsy.
  • A 65-year-old woman experienced chronic cough and was hospitalized with acute chest pain, where imaging revealed extensive lung inflammation.
  • The diagnosis was confirmed via bronchoscopy, leading to hormone anti-inflammatory treatment; however, the patient was lost to follow-up, emphasizing the need for awareness and biopsy in similar cases to ensure proper diagnosis and management of PPP.
View Article and Find Full Text PDF

Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.

Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.

View Article and Find Full Text PDF

Background: We conduct a retrospective analysis of patients with pathological fractures resulting from upper extremity malignancies, focusing on the evaluation of treatment strategies employed.

Materials And Methods: We retrospectively studied 10 patients with metastatic bone tumors of the upper extremities. The study variables included tumor site, primary pathology, duration from the first diagnosis of the primary lesion to the occurrence of the pathological fracture, use of bone-modifying drugs, surgical technique, adjuvant therapy, postoperative functional assessment, Katagiri's score, American Society of Anesthesiologists physical status (ASA-PS), outcome, and correlations between the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and Musculoskeletal Tumor Society (MSTS) score.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!